MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“The proto-oncogene MET, which enforces hepatocyte growth factor receptor (HGFR, also known as MET tyrosine kinase receptor), shares several downstream pathways with EGFR, including RAS/RAF/MAPK and PI3K/AKT signaling pathways [173,183].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [14]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Research works printed but not linked: 2
- J. G. Christensen et al., Cancer Res.63, 7345 (2003).
- F. M. Yakes et al., Cancer Res.62, 4132 (2002).
Cited by
Items 301–400 of 1,038
Nagano, T., Tachihara, M., & Nishimura, Y. (2018) · Cells · doi:10.3390/cells7110212 · Cited by 251
The MET receptor tyrosine kinase in invasion and metastasis
Benvenuti, S., & Comoglio, P. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21183 · Cited by 253
Evolution of acquired resistance to anti-cancer therapy
Foo, J., & Michor, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.02.025 · Cited by 254
Ware, K. E., Hinz, T. K., Kleczko, E., Singleton, K. R., Marek, L. A., Helfrich, B. A., Cummings, C. T., Graham, D. K., Astling, D., Tan, A.-C., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.4 · Cited by 249
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Janku, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 249
Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy
Ye, Y., Hu, Q., Chen, H., Liang, K., Yuan, Y., Xiang, Y., Ruan, H., Zhang, Z., Song, A., Zhang, H., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0045-8 · Cited by 250
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 250
Mutant BRAF Melanomas—Dependence and Resistance
Poulikakos, P. I., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 250
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J.-F., D'Hondt, L., Strauven, T., Chaskis, C., In't Veld, P., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 250
Yamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.008 · Cited by 249
Tsimberidou, A.-M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 249
“c-MET mutations are usually a result of sporadic somatic alterations acquired during cancer development [83, 84, 86, 87].”
InfluentialTyrosine kinase inhibitors: Multi-targeted or single-targeted?
Broekman, F. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i2.80 · Cited by 247
Cellular Homeostasis and Repair in the Mammalian Liver
Stanger, B. Z. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170255 · Cited by 248
“Thus, it will be particularly interesting to see whether double mutants lacking both EGF signaling and HGF signaling can regenerate liver mass, as these signaling pathways were previously shown to be redundant in other settings (108).”
Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils
Torti, D., & Trusolino, L. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100176 · Cited by 246
Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Chih-Hsin Yang, J., Reck, M., Yoh, K., Lee, S.-H., Paz-Ares, L., Besse, B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01476 · Cited by 246
“…kinase erbB-3 [ERBB3]) expression, which has been reported in 83% of NSCLC tumors 6 and in 85%-100% of tumors harboring an activating EGFR mutation, 7,8 is implicated in resistance to EGFR TKI therapy 9,10 and is associated with metastatic progression and shorter relapse-free survival.”
BackgroundSelf-citationMolecular pathology of lung cancer: key to personalized medicine
Cheng, L., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Lopez-Beltran, A., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 246
Molecular Biology of Lung Cancer: Clinical Implications
Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 245
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 264
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 244
“13 –15, 25, and Figure 2F).”
Small RNA combination therapy for lung cancer
Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412686111 · Cited by 242
Targeting TGF-β Signaling for Therapeutic Gain
Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 241
Kasinski, A. L., & Slack, F. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2001 · Cited by 242
Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., & Bentires-Alj, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.023 · Cited by 240
The ERBB3 receptor in cancer and cancer gene therapy
Sithanandam, G., & Anderson, L. M. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.15 · Cited by 240
Han, W., & Lo, H.-W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.011 · Cited by 240
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research
Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L., & Minna, J. D. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq279 · Cited by 239
Kazandjian, D., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2266 · Cited by 236
PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer
Pérez-Ramírez, C., Cañadas-Garre, M., Molina, M. Á., Faus-Dáder, M. J., & Calleja-Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.122 · Cited by 236
Hepatocyte growth factor/MET in cancer progression and biomarker discovery
Matsumoto, K., Umitsu, M., De Silva, D. M., Roy, A., & Bottaro, D. P. (2017) · Cancer Science · doi:10.1111/cas.13156 · Cited by 239
Epidermal growth factor receptor mutations in lung adenocarcinoma
Siegelin, M. D., & Borczuk, A. C. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 235
Yang, C.-H., Yu, C.-J., Shih, J.-Y., Chang, Y.-C., Hu, F.-C., Tsai, M.-C., Chen, K.-Y., Lin, Z.-Z., Huang, C.-J., Shun, C.-T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6695 · Cited by 235
Beretta, G. L., Cassinelli, G., Pennati, M., Zuco, V., & Gatti, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.062 · Cited by 235
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z., Thomas, R. K., Greulich, H., Schinzel, A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.047 · Cited by 234
Resisting Resistance: Targeted Therapies in Lung Cancer
Lin, J. J., & Shaw, A. T. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 232
Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma
Lee, J. J.-K., Park, S., Park, H., Kim, S., Lee, J., Lee, J., Youk, J., Yi, K., An, Y., Park, I. K., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.013 · Cited by 233
Du, J., Bernasconi, P., Clauser, K. R., Mani, D. R., Finn, S. P., Beroukhim, R., Burns, M., Julian, B., Peng, X. P., Hieronymus, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1513 · Cited by 232
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Kuang, Y., Rogers, A., Yeap, B. Y., Wang, L., Makrigiorgos, M., Vetrand, K., Thiede, S., Distel, R. J., & Jänne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 232
Self-citationMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-75 · Cited by 231
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
Knowles, L. M., Stabile, L. P., Egloff, A. M., Rothstein, M. E., Thomas, S. M., Gubish, C. T., Lerner, E. C., Seethala, R. R., Suzuki, S., Quesnelle, K. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3252 · Cited by 231
Biology and evolution of poorly differentiated neuroendocrine tumors
Rickman, D. S., Beltran, H., Demichelis, F., & Rubin, M. A. (2017) · Nature Medicine · doi:10.1038/nm.4341 · Cited by 231
Lin, J. J., Liu, S. V., McCoach, C. E., Zhu, V. W., Tan, A. C., Yoda, S., Peterson, J., Do, A., Prutisto-Chang, K., Dagogo-Jack, I., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.015 · Cited by 227
Xiang, Q., Chen, W., Ren, M., Wang, J., Zhang, H., Deng, D. Y. B., Zhang, L., Shang, C., & Chen, Y. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2620 · Cited by 229
Chromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
Ercan, D., Zejnullahu, K., Yonesaka, K., Xiao, Y., Capelletti, M., Rogers, A., Lifshits, E., Brown, A., Lee, C., Christensen, J. G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.526 · Cited by 228
Self-citationDecorin is a novel antagonistic ligand of the Met receptor
Goldoni, S., Humphries, A., Nyström, A., Sattar, S., Owens, R. T., McQuillan, D. J., Ireton, K., & Iozzo, R. V. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200901129 · Cited by 227
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Suda, K., Onozato, R., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913c9f · Cited by 226
Self-citationZheng, D., Ye, X., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 226
Murtuza, A., Bulbul, A., Shen, J. P., Keshavarzian, P., Woodward, B. D., Lopez-Diaz, F. J., Lippman, S. M., & Husain, H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1281 · Cited by 226
Francies, F. Z., Hull, R., Khanyile, R., & Dlamini, Z. (2020) · PubMed · Cited by 381
Eck, M. J., & Yun, C.-H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.010 · Cited by 225
Mechanisms of Acquired Resistance to AZD9291
Kim, T. M., Song, A., Kim, D.-W., Kim, S., Ahn, Y.-O., Keam, B., Jeon, Y. K., Lee, S.-H., Chung, D. H., & Heo, D. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000688 · Cited by 222
Recondo, G., Bahcall, M., Spurr, L. F., Che, J., Ricciuti, B., Leonardi, G. C., Lo, Y.-C., Li, Y. Y., Lamberti, G., Nguyen, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3608 · Cited by 220
Self-citationTargeting MET Dysregulation in Cancer
Recondo, G., Che, J., Jänne, P. A., & Awad, M. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1446 · Cited by 221
Self-citationHGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
Marek, L., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.049544 · Cited by 222
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Mateos, J. F., Vatsiou, A., Lampis, A., Damavandi, M. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0891 · Cited by 225
Targeting the HGF/Met signaling pathway in cancer therapy
Cecchi, F., Rabe, D. C., & Bottaro, D. P. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.680957 · Cited by 222
EGFR and NF-κB: partners in cancer
Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 220
Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics
Pan, C., Olsen, J. V., Daub, H., & Mann, M. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900285-mcp200 · Cited by 220
Gelatti, A. C. Z., Drilon, A., & Santini, F. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.017 · Cited by 220
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“The other common mechanism of acquired resistance to EGFR tyrosine kinase inhibition involves amplification of RTK c-MET [41], a proto-oncogene that encodes a protein also known as hepatocyte growth factor receptor (HGFR),.”
BackgroundYano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Mitsudomi, T., Tanaka, H., Kimura, T., Kudoh, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823ab0dd · Cited by 220
Self-citationRho, J. K., Choi, Y. J., Lee, J. K., Ryoo, B.-Y., Na, I. I., Yang, S. H., Kim, C. H., & Lee, J. C. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.017 · Cited by 220
High-throughput kinase profiling as a platform for drug discovery
Goldstein, D. M., Gray, N. S., & Zarrinkar, P. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2541 · Cited by 215
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Go, H., Jeon, Y. K., Park, H. J., Sung, S.-W., Seo, J.-W., & Chung, D. H. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ce3d1d · Cited by 218
Qi, J., McTigue, M. A., Rogers, A., Lifshits, E., Christensen, J. G., Jänne, P. A., & Engelman, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1623 · Cited by 216
Self-citationTherapy for metastatic melanoma: the past, present, and future
Finn, L., Markovic, S. N., & Joseph, R. W. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-23 · Cited by 218
Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells
Todaro, M., Iovino, F., Eterno, V., Cammareri, P., Gambara, G., Espina, V., Gulotta, G., Dieli, F., Giordano, S., De Maria, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1994 · Cited by 218
Heon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 214
Self-citationTargeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Self-citationBuck, E., Gokhale, P. C., Koujak, S., Brown, E., Eyzaguirre, A., Tao, N., Rosenfeld-Franklin, M., Lerner, L., Chiu, M. I., Wild, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0318 · Cited by 216
Liu, X., Wang, P., Zhang, C., & Ma, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.16854 · Cited by 216
Mechanisms and management of doxorubicin cardiotoxicity
Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. P. (2011) · Herz · doi:10.1007/s00059-011-3470-3 · Cited by 215
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-hara, T., Song, Y., Engelman, J. A., & Fujita, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3256 · Cited by 213
Self-citationHaber, D. A., Gray, N. S., & Baselga, J. (2011) · Cell · doi:10.1016/j.cell.2011.03.026 · Cited by 214
Papadimitrakopoulou, V. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825493eb · Cited by 215
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
Cui, J. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401427c · Cited by 209
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13665 · Cited by 214
Targeting the PI3K-AKT-mTOR signaling network in cancer
Khan, K. H., Yap, T. A., Yan, L., & Cunningham, D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.013.10057 · Cited by 213
Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 212
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
Puri, N., & Salgia, R. (2008) · Journal of Carcinogenesis · doi:10.4103/1477-3163.44372 · Cited by 211
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Crosstalk in Met receptor oncogenesis
Lai, A. Z., Abella, J. V., & Park, M. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.07.002 · Cited by 213
Precision medicine in non-small cell lung cancer: Current applications and future directions
Yang, S.-R., Schultheis, A. M., Yu, H., Mandelker, D., Ladanyi, M., & Büttner, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.009 · Cited by 209
Galdy, S., Lamarca, A., McNamara, M. G., Hubner, R. A., Cella, C. A., Fazio, N., & Valle, J. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9645-x · Cited by 209
An analysis of genetic heterogeneity in untreated cancers
Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., Daud, A., Iacobuzio-Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0185-x · Cited by 209
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Self-citationTargeting the HGF/Met signalling pathway in cancer
Cecchi, F., Rabe, D. C., & Bottaro, D. P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.028 · Cited by 209
Kim, S., Lee, U. J., Kim, M. N., Lee, E.-J., Kim, J. Y., Lee, M. Y., Choung, S., Kim, Y. J., & Choi, Y.-C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800186200 · Cited by 210
Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210
Molecular biology of lung cancer: Clinical implications
Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 209
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 209
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
Tricker, E. M., Xu, C., Uddin, S., Capelletti, M., Ercan, D., Ogino, A., Pratilas, C. A., Rosen, N., Gray, N. S., Wong, K.-K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0063 · Cited by 209
Self-citationBasic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer
Willers, H., Azzoli, C. G., Santivasi, W. L., & Xia, F. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318292e4e3 · Cited by 208
John, T., Liu, G., & Tsao, M.-S. (2009) · Oncogene · doi:10.1038/onc.2009.197 · Cited by 207
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Maroun, C. R., & Rowlands, T. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.014 · Cited by 206
Terai, H., Soejima, K., Yasuda, H., Nakayama, S., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Ikemura, S., Sato, T., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0652 · Cited by 206
Godin-Heymann, N., Ulkus, L., Brannigan, B. W., McDermott, U., Lamb, J., Maheswaran, S., Settleman, J., & Haber, D. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2387 · Cited by 203
Metadata
- Authors
- Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., & Jänne, P. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- ORCID
- Venue
- Science
- Published
- 2007-05-18
- Volume
- 316
- Issue
- 5827
- Pages
- 1039-1043
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1998971866
- Cited by
- 4,496
- References
- 22
- Citations by year
- 2026: 97 · 2025: 109 · 2024: 123 · 2023: 136 · 2022: 152 · 2021: 191 · 2020: 182 · 2019: 214 · 2018: 269 · 2017: 288 · 2016: 291 · 2015: 375 · 2014: 349 · 2013: 369 · 2012: 345
- FWCI
- 207.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca111560-05)
- National Cancer Institute (R01-CA111560, P01CA089021, R01CA114465, P20CA090578, P20 CA 90578-02, 1K12CA87723-01, K08CA120060, K12CA087723)
- National Institute of General Medical Sciences (GM 41890, R01GM041890)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MET amplification, gefitinib resistance, lung cancer, HER3, PI3K signaling, EGFR kinase inhibitors, erlotinib, drug resistance, ErbB receptors, MET oncogene
- MeSH terms
- Gefitinib, Proto-Oncogene Mas, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cricetulus, Enzyme Inhibitors, Gene Amplification, Cricetinae, Humans, Indoles, Lung Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Sulfones, Signal Transduction, CHO Cells, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Receptor, ErbB-3, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.